Shionogi & Co.,Ltd. Logo

Shionogi & Co.,Ltd.

A research-driven pharmaceutical firm creating drugs, diagnostics, and devices for global health.

4507 | T

Overview

Corporate Details

ISIN(s):
JP3347200002
LEI:
Country:
Japan
Address:
大阪市中央区道修町3丁目1番8号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shionogi & Co., Ltd. is a research-driven pharmaceutical company focused on the discovery, development, manufacturing, and marketing of pharmaceuticals, diagnostic reagents, and medical devices. With a history of over 140 years, the company is dedicated to creating innovative products and services that deliver value to patients and society globally. As a drug discovery-based organization, Shionogi leverages its robust research and development pipeline to address unmet medical needs and contribute to the health of people worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 03:07
Registration Form
確認書
Japanese 8.9 KB
2025-11-07 03:05
Interim Report
半期報告書-第161期(2025/04/01-2026/03/31)
Japanese 327.3 KB
2025-09-25 08:53
M&A Activity
訂正臨時報告書
Japanese 48.0 KB
2025-06-19 09:24
Post-Annual General Meeting Information
臨時報告書
Japanese 30.7 KB
2025-06-19 09:14
Governance Information
内部統制報告書-第160期(2024/04/01-2025/03/31)
Japanese 30.2 KB
2025-06-19 09:12
Registration Form
確認書
Japanese 8.9 KB
2025-06-19 09:10
Annual Report
有価証券報告書-第160期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2025-06-19 08:07
M&A Activity
公開買付報告書
Japanese 41.6 KB
2025-06-19 06:40
Major Shareholding Notification
大量保有報告書
Japanese 61.0 KB
2025-06-18 08:49
Share Issue/Capital Change
臨時報告書
Japanese 41.9 KB
2025-06-04 08:39
M&A Activity
訂正公開買付届出書
Japanese 258.4 KB
2025-05-28 08:38
M&A Activity
訂正公開買付届出書
Japanese 262.0 KB
2025-05-08 05:52
M&A Activity
公開買付届出書
Japanese 530.2 KB
2025-05-07 09:12
M&A Activity
臨時報告書
Japanese 50.3 KB
2024-11-08 02:44
Interim Report
確認書
Japanese 9.0 KB

Automate Your Workflow. Get a real-time feed of all Shionogi & Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shionogi & Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shionogi & Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Whitehawk Therapeutics, Inc. Logo
Develops advanced antibody-drug conjugates (ADCs) for difficult-to-treat cancers.
United States of America
WHWK
WooGeneB&GCO.,Ltd Logo
Manufactures veterinary medicines, vaccines, and supplements for livestock and aquatic animals.
South Korea
018620
X4 Pharmaceuticals, Inc Logo
Developing and commercializing novel therapies for rare diseases of the immune system.
United States of America
XFOR
XBiotech Inc. Logo
Develops therapeutic antibodies from natural human immunity for inflammatory diseases and oncology.
United States of America
XBIT
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden
XBRANE
Xencor Inc Logo
Engineering antibody & cytokine therapeutics for cancer and autoimmune diseases via its XmAb platform.
United States of America
XNCR
Xenon Pharmaceuticals Inc. Logo
A neuroscience biopharma developing novel therapeutics for epilepsy and depression.
United States of America
XENE
Xeris Biopharma Holdings, Inc. Logo
Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.
United States of America
XERS
Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden
XINT
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY

Talk to a Data Expert

Have a question? We'll get back to you promptly.